US FDA classifies dressings containing pDADMAC as Class II
This article was originally published in RAJ Devices
The US Food and Drug Administration is classifying wound dressings that contain the additive poly (diallyl dimethyl ammonium chloride) as Class II devices and has issued a guidance document on special controls that must be followed by manufacturers intending to market such products1-3.
You may also be interested in...
Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.
The Therapeutic Goods Administration’s provisional approval for Gilead Sciences’ drug comes with a number of post-marketing obligations for the company.
Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.